View More View Less
  • 1 Semmelweis Egyetem, Általános Orvotudományi Kar II. Patológiai Intézet Budapest Üllői út 93. 1091
  • 2 Semmelweis Egyetem, Általános Orvostudományi Kar I. Sebészeti Klinika Budapest
  • 3 Magyar Tudományos Akadémia Gyermekgyógyászati és Nefrológiai Kutatólaboratórium Budapest
  • 4 Magyar Tudományos Akadémia–Semmelweis Egyetem Daganatprogresszió Kutatócsoport Budapest
  • 5 Semmelweis Egyetem, Általános Orvostudományi Kar Ortopédiai Klinika Budapest
  • 6 Technical University of Denmark Center for Biological Sequence Analysis, BioCentrum Lyngby Kgs Dánia
  • 7 Harvard Medical School Informatics Program, Children’s Hospital Boston Boston MA Amerikai Egyesült Államok
  • 8 London Research Institute, Translational Cancer Therapeutics Laboratory Cancer Research UK London Egyesült Királyság
  • 9 University College London Cancer Institute London WC1E 6BT, London Egyesült Királyság
Open access

Bevezetés: Közepesen differenciált (grade 2) tumorok esetén a beteg prognózisa és a terápia eredményessége e tényező alapján nem becsülhető meg biztonsággal. Célkitűzés: Vizsgálni a szerzők által leírt, kromoszomális instabilitást tükröző prognosztikus génexpressziós indexet kiegészítve további génekkel egy kiterjesztett betegcsoporton. Módszerek: Publikus adatbázisokból választottak ki kilenc cél-, valamint három kontrollgént. Ezek expresszióját valós idejű polimeráz láncreakcióval határozták meg. Az analízisben 249, formalinban fixált, paraffinba ágyazott emlőcarcinoma vizsgálatát végezték el és az eredményeiket a betegségmentes túléléssel összefüggésben elemezték. Eredmények: A gének expressziójának mértéke alapján a grade 2 carcinomák a grade 1, illetve a grade 3 tumorokhoz hasonló prognózisú csoportokra különültek el. Pusztán a FOXM1, TOP2A és CLDN4 gének együttes vizsgálatával a grade 2 daganatok magas és alacsony kockázatú alcsoportokba oszthatóak. Következtetés: Megfelelően választott kontrollgének vizsgálatával három célgén expressziója alapján a hisztológiai grade-től függetlenül elkülöníthető az emlőcarcinomák jó és rossz prognózisú csoportja. Orv. Hetil., 2013, 154, 627–632.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • Elston, C. W., Ellis, I. O.: Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology, 1991, 19, 403–410.

    Ellis I. O. , 'Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up ' (1991 ) 19 Histopathology : 403 -410.

    • Search Google Scholar
  • Galea, M. H., Blamey, R. W., Elston, C. E., et al.: The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res. Treat., 1992, 22, 207–219.

    Elston C. E. , 'The Nottingham Prognostic Index in primary breast cancer ' (1992 ) 22 Breast Cancer Res. Treat. : 207 -219.

    • Search Google Scholar
  • Rakha, E. A., El-Sayed, M. E., Lee, A. H., et al.: Prognostic significance of Nottingham histologic grade in invasive breast carcinoma. J. Clin. Oncol., 2008, 26, 3153–3158.

    Lee A. H. , 'Prognostic significance of Nottingham histologic grade in invasive breast carcinoma ' (2008 ) 26 J. Clin. Oncol. : 3153 -3158.

    • Search Google Scholar
  • Dalton, L. W., Pinder, S. E., Elston, C. E., et al.: Histologic grading of breast cancer: linkage of patient outcome with level of pathologist agreement. Mod. Pathol., 2000, 13, 730–735.

    Elston C. E. , 'Histologic grading of breast cancer: linkage of patient outcome with level of pathologist agreement ' (2000 ) 13 Mod. Pathol. : 730 -735.

    • Search Google Scholar
  • Perou, C. M., Sørlie, T., Eisen, M. B., et al.: Molecular portraits of human breast tumours. Nature, 2000, 406, 747–752.

    Eisen M. B. , 'Molecular portraits of human breast tumours ' (2000 ) 406 Nature : 747 -752.

  • Van’t Veer, L. J., Dai, H., van de Vijver, M. J., et al.: Gene expression profiling predicts clinical outcome of breast cancer. Nature, 2002, 415, 530–536.

    Vijver M. J. , 'Gene expression profiling predicts clinical outcome of breast cancer ' (2002 ) 415 Nature : 530 -536.

    • Search Google Scholar
  • Paik, S., Shak, S., Tang, G., et al.: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med., 2004, 351, 2817–2826.

    Tang G. , 'A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer ' (2004 ) 351 N. Engl. J. Med. : 2817 -2826.

    • Search Google Scholar
  • Van de Vijver, M. J., He, Y. D., Van’t Veer, L. J., et al.: A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med., 2002, 347, 1999–2009.

    Veer L. J. , 'A gene-expression signature as a predictor of survival in breast cancer ' (2002 ) 347 N. Engl. J. Med. : 1999 -2009.

    • Search Google Scholar
  • Sotiriou, C., Wirapati, P., Loi, S., et al.: Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J. Natl. Cancer Inst., 2006, 98, 262–272.

    Loi S. , 'Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis ' (2006 ) 98 J. Natl. Cancer Inst. : 262 -272.

    • Search Google Scholar
  • Ignatiadis, M., Sotiriou, C.: Understanding the molecular basis of histologic grade. Pathobiology, 2008, 75, 104–111.

    Sotiriou C. , 'Understanding the molecular basis of histologic grade ' (2008 ) 75 Pathobiology : 104 -111.

    • Search Google Scholar
  • Ivshina, A. V., George, J., Senko, O., et al.: Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. Cancer Res., 2006, 66, 10292–10301.

    Senko O. , 'Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer ' (2006 ) 66 Cancer Res. : 10292 -10301.

    • Search Google Scholar
  • Carter, S. L., Eklund, A. C., Kohane, I. S., et al.: A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers. Nat. Genet., 2006, 38, 1043–1048.

    Kohane I. S. , 'A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers ' (2006 ) 38 Nat. Genet. : 1043 -1048.

    • Search Google Scholar
  • Szasz, A. M., Li, Q., Eklund, A., et al.: The CIN4 chromosomal instability qPCR classifier defines tumor aneuploidy and stratifies outcome in grade 2 breast cancer. PLoS One, 2013, DOI:10.1371/journal.pone.0056707

    Eklund A. , 'The CIN4 chromosomal instability qPCR classifier defines tumor aneuploidy and stratifies outcome in grade 2 breast cancer ' (2013 ) PLoS One : -.

    • Search Google Scholar
  • Miller, L. D., Smeds, J., George, J., et al.: An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc. Natl. Acad. Sci. USA, 2005, 102, 13550–13555.

    George J. , 'An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival ' (2005 ) 102 Proc. Natl. Acad. Sci. USA : 13550 -13555.

    • Search Google Scholar
  • Kulka, J., Szasz, A. M., Nemeth, Z., et al.: Expression of tight junction protein claudin-4 in basal-like breast carcinomas. Pathol. Oncol. Res., 2009, 15, 59–64.

    Nemeth Z. , 'Expression of tight junction protein claudin-4 in basal-like breast carcinomas ' (2009 ) 15 Pathol. Oncol. Res. : 59 -64.

    • Search Google Scholar
  • Szasz, A. M., Nemeth, Z., Gyorffy, B., et al.: Identification of a claudin-4 and E-cadherin score (CURIO) to predict prognosis in breast cancer. Cancer Sci., 2011, 102, 2248–2254.

    Gyorffy B. , 'Identification of a claudin-4 and E-cadherin score (CURIO) to predict prognosis in breast cancer ' (2011 ) 102 Cancer Sci. : 2248 -2254.

    • Search Google Scholar
  • Tibshirani, R., Hastie, T., Narasimhan, B., et al.: Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc. Natl. Acad. Sci. USA, 2002, 99, 6567–6572.

    Narasimhan B. , 'Diagnosis of multiple cancer types by shrunken centroids of gene expression ' (2002 ) 99 Proc. Natl. Acad. Sci. USA : 6567 -6572.

    • Search Google Scholar
  • Lyng, M. B., Laenkholm, A. V., Pallisgaard, N., et al.: Identification of genes for normalization of real-time RT-PCR data in breast carcinomas. BMC Cancer, 2008, 8, 20.

    Pallisgaard N. , 'Identification of genes for normalization of real-time RT-PCR data in breast carcinomas ' (2008 ) 8 BMC Cancer : 20 -.

    • Search Google Scholar
  • Toussaint, J., Sieuwerts, A. M., Haibe-Kains, B., et al.: Improvement of the clinical applicability of the Genomic Grade Index through a qRT-PCR test performed on frozen and formalin-fixed paraffin-embedded tissues. BMC Genomics, 2009, 10, 424.

    Haibe-Kains B. , 'Improvement of the clinical applicability of the Genomic Grade Index through a qRT-PCR test performed on frozen and formalin-fixed paraffin-embedded tissues ' (2009 ) 10 BMC Genomics : 424 -.

    • Search Google Scholar
  • Ma, X. J., Salunga, R., Dahiya, S., et al.: A five-gene molecular grade index and HOXB13:IL17BR are complementary prognostic factors in early stage breast cancer. Clin. Cancer Res., 2008, 14, 2601–2608.

    Dahiya S. , 'A five-gene molecular grade index and HOXB13:IL17BR are complementary prognostic factors in early stage breast cancer ' (2008 ) 14 Clin. Cancer Res. : 2601 -2608.

    • Search Google Scholar
  • Järvinen, T. A., Holli, K., Kuukasjärvi, T., et al.: Predictive value of topoisomerase II alpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer. Br. J. Cancer, 1998, 77, 2267–2273.

    Kuukasjärvi T. , 'Predictive value of topoisomerase II alpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer ' (1998 ) 77 Br. J. Cancer : 2267 -2273.

    • Search Google Scholar
  • Järvinen, T. A., Tanner, M., Rantanen, V., et al.: Amplification and deletion of topoisomerase II alpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Am. J. Pathol., 2000, 156, 839–847.

    Rantanen V. , 'Amplification and deletion of topoisomerase II alpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer ' (2000 ) 156 Am. J. Pathol. : 839 -847.

    • Search Google Scholar
  • O’Malley, F. P., Chia, S., Tu, D., et al.: Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy. J. Natl. Cancer Inst., 2009, 101, 644–650.

    Tu D. , 'Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy ' (2009 ) 101 J. Natl. Cancer Inst. : 644 -650.

    • Search Google Scholar
  • Tsukita, S., Furuse, M.: The structure and function of claudins, cell adhesion molecules at tight junctions. Ann. N. Y. Acad. Sci., 2000, 915, 129–135.

    Furuse M. , 'The structure and function of claudins, cell adhesion molecules at tight junctions ' (2000 ) 915 Ann. N. Y. Acad. Sci. : 129 -135.

    • Search Google Scholar
  • Blanchard, A. A., Skliris, G. P., Watson, P. H., et al.: Claudins 1, 3, and 4 protein expression in ER negative breast cancer correlates with markers of the basal phenotype. Virchows Arch., 2009, 454, 647–656.

    Watson P. H. , 'Claudins 1, 3, and 4 protein expression in ER negative breast cancer correlates with markers of the basal phenotype ' (2009 ) 454 Virchows Arch. : 647 -656.

    • Search Google Scholar
  • Herschkowitz, J. I., Simin, K., Weigman, V. J., et al.: Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol., 2007, 8, R76.

    Weigman V. J. , 'Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors ' (2007 ) 8 Genome Biol. : R76 -.

    • Search Google Scholar